163 related articles for article (PubMed ID: 32886033)
1. Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors.
Hassanzadeh M; Mahernia S; Caprini G; Fossati G; Adib M; Moakedi F; Amanlou M
J Biomol Struct Dyn; 2022 Jan; 40(1):297-311. PubMed ID: 32886033
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
3. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
Thangapandian S; John S; Lee Y; Kim S; Lee KW
Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
[TBL] [Abstract][Full Text] [Related]
4. Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Uba AI; Weako J; Keskin Ö; Gürsoy A; Yelekçi K
J Biomol Struct Dyn; 2020 Apr; 38(6):1751-1760. PubMed ID: 31057077
[TBL] [Abstract][Full Text] [Related]
5. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential histone deacetylase1 (HDAC1) inhibitors using multistep virtual screening approach including SVM model, pharmacophore modeling, molecular docking and biological evaluation.
Krishna S; Lakra AD; Shukla N; Khan S; Mishra DP; Ahmed S; Siddiqi MI
J Biomol Struct Dyn; 2020 Jul; 38(11):3280-3295. PubMed ID: 31411124
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel HDAC8 inhibitors from natural compounds by in silico high throughput screening.
Esther Rubavathy SM; Palanisamy K; Priyankha S; Thilagavathi R; Prakash M; Selvam C
J Biomol Struct Dyn; 2023 Nov; 41(19):9492-9502. PubMed ID: 36369945
[TBL] [Abstract][Full Text] [Related]
8. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
Hassanzadeh M; Bagherzadeh K; Amanlou M
J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
Hou X; Du J; Liu R; Zhou Y; Li M; Xu W; Fang H
J Chem Inf Model; 2015 Apr; 55(4):861-71. PubMed ID: 25757142
[TBL] [Abstract][Full Text] [Related]
10. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
11. Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Dewaker V; Srivastava AK; Arora A; Prabhakar YS
J Biomol Struct Dyn; 2021 Aug; 39(13):4726-4751. PubMed ID: 32578494
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
[TBL] [Abstract][Full Text] [Related]
13. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
16. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
17. Screening of novel histone deacetylase 7 inhibitors through molecular docking followed by a combination of molecular dynamics simulations and ligand-based approach.
Yuan Y; Hu Z; Bao M; Sun R; Long X; Long L; Li J; Wu C; Bao J
J Biomol Struct Dyn; 2019 Sep; 37(15):4092-4103. PubMed ID: 30417746
[TBL] [Abstract][Full Text] [Related]
18. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
20. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
